Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.

Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska I, Santilli G, Gibson S, Sebire NJ, Himoudi N, Hogarty MD, Anderson J, Bettuzzi S, Thomas-Tikhonenko A, Sala A.

J Natl Cancer Inst. 2009 May 6;101(9):663-77. doi: 10.1093/jnci/djp063. Epub 2009 Apr 28.

2.

ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux.

Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C, Murray J, Flemming CL, Smith J, Fletcher JI, Gherardi S, Kwek CK, Russell AJ, Valli E, London WB, Buxton AB, Ashton LJ, Sartorelli AC, Cohn SL, Schwab M, Marshall GM, Perini G, Norris MD.

J Natl Cancer Inst. 2011 Aug 17;103(16):1236-51. doi: 10.1093/jnci/djr256. Epub 2011 Jul 28.

3.

Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma.

Burkhart CA, Cheng AJ, Madafiglio J, Kavallaris M, Mili M, Marshall GM, Weiss WA, Khachigian LM, Norris MD, Haber M.

J Natl Cancer Inst. 2003 Sep 17;95(18):1394-403.

4.

CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.

Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, Maris JM, White PS, Brodeur GM.

J Natl Cancer Inst. 2008 Jul 2;100(13):940-9. doi: 10.1093/jnci/djn176. Epub 2008 Jun 24.

5.

MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.

Huang R, Cheung NK, Vider J, Cheung IY, Gerald WL, Tickoo SK, Holland EC, Blasberg RG.

FASEB J. 2011 Dec;25(12):4138-49. doi: 10.1096/fj.11-185033. Epub 2011 Aug 19.

6.

A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.

Shohet JM, Ghosh R, Coarfa C, Ludwig A, Benham AL, Chen Z, Patterson DM, Barbieri E, Mestdagh P, Sikorski DN, Milosavljevic A, Kim ES, Gunaratne PH.

Cancer Res. 2011 Jun 1;71(11):3841-51. doi: 10.1158/0008-5472.CAN-10-4391. Epub 2011 Apr 15.

7.

Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.

Li Y, Zhang B, Zhang H, Zhu X, Feng D, Zhang D, Zhuo B, Li L, Zheng J.

J Cancer Res Clin Oncol. 2013 Jun;139(6):933-41. doi: 10.1007/s00432-013-1406-4. Epub 2013 Feb 27.

PMID:
23443256
8.

Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.

Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, Ludwig A, Shohet JM.

Neoplasia. 2009 Aug;11(8):753-62.

9.

High mobility group A1 is a molecular target for MYCN in human neuroblastoma.

Giannini G, Cerignoli F, Mellone M, Massimi I, Ambrosi C, Rinaldi C, Dominici C, Frati L, Screpanti I, Gulino A.

Cancer Res. 2005 Sep 15;65(18):8308-16.

10.

MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2.

Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, Buckley PG, Ryan J, O'Meara A, O'Sullivan M, Stallings RL.

Mol Cancer. 2010 Apr 21;9:83. doi: 10.1186/1476-4598-9-83.

11.

Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.

Liu PY, Erriquez D, Marshall GM, Tee AE, Polly P, Wong M, Liu B, Bell JL, Zhang XD, Milazzo G, Cheung BB, Fox A, Swarbrick A, Hüttelmaier S, Kavallaris M, Perini G, Mattick JS, Dinger ME, Liu T.

J Natl Cancer Inst. 2014 Jun 6;106(7). pii: dju113. doi: 10.1093/jnci/dju113. Print 2014 Jul. Erratum in: J Natl Cancer Inst. 2015 Jan;107(1):doi/10.1093/jnci/dju359.

12.

Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma.

Buechner J, Tømte E, Haug BH, Henriksen JR, Løkke C, Flægstad T, Einvik C.

Br J Cancer. 2011 Jul 12;105(2):296-303. doi: 10.1038/bjc.2011.220. Epub 2011 Jun 7.

13.

Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism.

Mandriota SJ, Valentijn LJ, Lesne L, Betts DR, Marino D, Boudal-Khoshbeen M, London WB, Rougemont AL, Attiyeh EF, Maris JM, Hogarty MD, Koster J, Molenaar JJ, Versteeg R, Ansari M, Gumy-Pause F.

Oncotarget. 2015 Jul 30;6(21):18558-76.

14.

MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.

Cortés C, Kozma SC, Tauler A, Ambrosio S.

Cell Oncol (Dordr). 2015 Oct;38(5):341-52. doi: 10.1007/s13402-015-0233-9. Epub 2015 Aug 26.

PMID:
26306783
15.

MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.

Creevey L, Ryan J, Harvey H, Bray IM, Meehan M, Khan AR, Stallings RL.

Mol Cancer. 2013 Mar 26;12:23. doi: 10.1186/1476-4598-12-23.

16.

MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.

Haug BH, Henriksen JR, Buechner J, Geerts D, Tømte E, Kogner P, Martinsson T, Flægstad T, Sveinbjørnsson B, Einvik C.

Carcinogenesis. 2011 Jul;32(7):1005-12. doi: 10.1093/carcin/bgr073. Epub 2011 May 13.

17.

miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis.

Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA.

Nat Cell Biol. 2010 Mar;12(3):247-56. doi: 10.1038/ncb2024. Epub 2010 Feb 21.

18.

Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.

Amente S, Milazzo G, Sorrentino MC, Ambrosio S, Di Palo G, Lania L, Perini G, Majello B.

Oncotarget. 2015 Jun 10;6(16):14572-83.

19.

miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.

Terrile M, Bryan K, Vaughan L, Hallsworth A, Webber H, Chesler L, Stallings RL.

PLoS One. 2011;6(12):e28356. doi: 10.1371/journal.pone.0028356. Epub 2011 Dec 2.

20.
Items per page

Supplemental Content

Write to the Help Desk